BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
Rajesh M ValanparambilLilin LaiMargaret A JohnsMeredith Davis-GardnerSusanne L LindermanTarrant Oliver McPhersonAndres ChangAkil AktharEstefany L Bocangel GamarraHayley MatiaAshley Alesia McCookJeffrey SwitchenkoTahseen H NastiFelicia GreenManpreet SainiAndreas WielandBenjamin A PinskyDaniel SolisMadhav V DhodapkarJennifer CarlisleSuresh RamalingamRafi AhmedMehul S SutharPublished in: NPJ vaccines (2023)
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4-6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- copy number
- epidermal growth factor receptor
- coronavirus disease
- healthcare
- sars cov
- palliative care
- emergency department
- brain metastases
- quality improvement
- machine learning
- adverse drug
- health insurance
- artificial intelligence
- respiratory syndrome coronavirus